Company Description
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States.
The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain.
It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate.
The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023.
Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2009 |
| IPO Date | Apr 5, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Carmine Stengone |
Contact Details
Address: 3565 General Atomics Court, Suite 200 San Diego, California 92121 United States | |
| Phone | 858 333 5280 |
| Website | contineum-tx.com |
Stock Details
| Ticker Symbol | CTNM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001855175 |
| CUSIP Number | 21217B100 |
| ISIN Number | US21217B1008 |
| Employer ID | 27-1467257 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Carmine N. Stengone MBA, MS | President, Chief Executive Officer and Director |
| Peter T. Slover CPA | Chief Financial Officer |
| Morgan Paulsen | Senior Manager of Accounting |
| Steve E. Kunszabo | Senior Director of Investor Relations and Corporate Communications |
| Austin Chen Ph.D. | Senior Vice President and Head of Research |
| Julie S. Iwashita | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 8-K | Current Report |
| Mar 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2025 | 10-K | Annual Report |
| Mar 6, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |